In this episode of MedOncNow, Dr. Sharlene Gill takes us through the evolving changes in the treatment of dMMR/MSI-H mCRC. Given that BMS has a company-sponsored PSP program, I felt it timely to discuss how Ipilimumab and Nivolumab fits into our treatment strategy.